When Lactulose Secondary Prophylaxis Fails After a First Episode of Overt Hepatic Encephalopathy

After a first overt episode of hepatic encephalopathy, secondary prophylaxis with lactulose is the established first-line approach. When that regimen does not achieve its intended target, a next-line intervention is warranted.

Clinical Scenario

The patient has a history of a first episode of overt hepatic encephalopathy and is currently on lactulose secondary prophylaxis, titrated to achieve 2–3 bowel movements per day. This protocol addresses the situation in which that target is not consistently met or recurrent overt HE episodes occur despite ongoing lactulose therapy.

Previous Line — Insufficient Response

Prior therapy: Lactulose (secondary prophylaxis, titrated to 2–3 bowel movements per day)

Target not reached: Consistent achievement of 2–3 bowel movements per day and prevention of further overt HE episodes

When lactulose alone fails to meet this target, the protocol described here represents the recommended escalation step.

Next-Line Approach (Partial Overview)

The recommended escalation involves adding rifaximin as an adjunct to ongoing lactulose therapy. The full eligibility criteria, clinical decision points, and complete management details are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2022.06.001

Lactulose is recommended as secondary prophylaxis following a first episode of overt HE, and should be titrated to obtain 2-3 bowel movements per day (LoE 1, strong recommendation, 96% consensus).
Rifaximin as an adjunct to lactulose is recommended as secondary prophylaxis following ≥1 additional episodes of overt HE within 6 months of the first one (LoE 2, strong recommendation, 92% consensus).

View source ↗